Humana (NYSE:HUM) Raised to Outperform at Royal Bank Of Canada

Humana (NYSE:HUM – Get Free Report) was upgraded by Royal Bank Of Canada from a “sector perform” rating to an “outperform” rating in a report released on Monday, Marketbeat.com reports. The firm presently has a $563.00 price target on the insurance provider’s stock, up from their previous price target of $415.00. Royal Bank Of Canada‘s price objective indicates a potential upside of 25.01% from the stock’s previous close.

A number of other equities research analysts have also weighed in on HUM. Guggenheim boosted their price target on Humana from $471.00 to $521.00 and gave the stock a “buy” rating in a research note on Monday, November 9th. Leerink Partners upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $513.00 price objective on the stock in a report on Thursday, July 30th. Truist Financial increased their price objective on shares of Humana from $415.00 to $475.00 and gave the company a “hold” rating in a research report on Monday, October 12th. Weiss Ratings reiterated a “hold (c)” rating on shares of Humana in a research note on Thursday. Finally, Monness Crespi & Hardt raised shares of Humana to a “buy” rating in a research report on Friday, October 9th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $482.96.

Check Out Our Latest Stock Analysis on HUM

Humana Stock Up 0.1%

Humana stock opened at $450.38 on Monday. Humana has a 1-year low of $163.11 and a 1-year high of $456.50. The business has a fifty day moving average price of $408.53 and a 200-day moving average price of $316.91. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.65 and a quick ratio of 1.65. The stock has a market capitalization of $54.09 billion, a price-to-earnings ratio of 43.81, a PEG ratio of 2.14 and a beta of 0.65.

Humana (NYSE:HUM – Get Free Report) last announced its earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.30. Humana had a return on equity of 8.50% and a net margin of 0.81%. The company had revenue of $41.16 billion for the quarter, compared to analyst estimates of $40.87 billion. During the same period in the prior year, the company posted $3.24 EPS. The firm’s quarterly revenue was up 26.1% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.500- EPS. Equities research analysts forecast that Humana will post 9.66 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Joseph Ventura sold 5,495 shares of the stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $433.85, for a total value of $2,384,005.75. Following the transaction, the insider directly owned 21,910 shares of the company’s stock, valued at approximately $9,505,653.50. This represents a 20.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.20% of the company’s stock.

Institutional Investors Weigh In On Humana

A number of large investors have recently bought and sold shares of HUM. BlackRock Inc. purchased a new position in Humana during the 2nd quarter worth approximately $4,138,160,000. State Street Corp lifted its stake in Humana by 1.6% during the 3rd quarter. State Street Corp now owns 5,543,942 shares of the insurance provider’s stock valued at $2,115,402,000 after acquiring an additional 86,870 shares during the period. Pzena Investment Management LLC purchased a new stake in shares of Humana in the 2nd quarter valued at $1,749,014,000. Assenagon Asset Management S.A. boosted its holdings in shares of Humana by 20,126.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider’s stock valued at $479,053,000 after acquiring an additional 1,249,272 shares during the last quarter. Finally, Legal & General Group Plc purchased a new stake in shares of Humana in the 2nd quarter valued at $329,760,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

(Get Free Report)

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.

See Also

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.